Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

CombinatoRx, Angiotech in combination drug discovery alliance

Executive Summary

CombinatoRx (combines approved drugs to simultaneously target multiple disease pathways and create effects that are different from those of each drug alone) and Angiotech Pharmaceuticals (drug-coated medical devices and biomaterials) will jointly discover and develop local drug/device combinations in fields of interest to Angiotech. These areas will initially be vascular and orthopedic disorders, surgical adhesions, and local tumor management.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies